Status:

COMPLETED

Continued Access to the Recell® Device for Treatment of Acute Burn Injuries

Lead Sponsor:

Avita Medical

Collaborating Sponsors:

Advanced Clinical Research Services, LLC

Conditions:

Burns

Eligibility:

All Genders

5+ years

Brief Summary

The overall purpose of this continued access study is to allow ongoing treatment of subjects at selected investigational sites while the marketing application for the ReCell® Autologous Cell Harvestin...

Detailed Description

Patients 5 years or older with a total body surface area (TBSA) thermal burn injury between 5 and 50% (inclusive) who require autografting will be considered for participation in this study. RES (Rege...

Eligibility Criteria

Inclusion

  • The subject requires skin grafting as a result of an acute thermal burn injury (i.e., injuries caused by exposure of the skin to fire/flames, excessive heat, hot steam or water).
  • The area of total burn injury is 5-50% TBSA inclusive.
  • Area(s) requiring skin grafting at least 320 square centimeters.
  • The subject is at least 5 years of age.
  • The subject (or family, for those under 18 years of age) is willing and able to complete all follow-up evaluations required by the study protocol.
  • The subject is to abstain from any other treatment of the wound(s) for the duration of the study unless medically necessary.
  • The subject agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study.
  • The subject and/or guardian are able to read and understand instructions and give informed, voluntary, written consent.

Exclusion

  • The subject's burn injuries were caused by chemicals, electricity, and/or radioactive substances.
  • The subject is unable to follow the protocol.
  • The subject has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives.
  • The subject has a known hypersensitivity to trypsin or compound sodium lactate for irrigation (Hartmann's) solution.
  • Pregnant or lactating women.

Key Trial Info

Start Date :

October 26 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 8 2019

Estimated Enrollment :

76 Patients enrolled

Trial Details

Trial ID

NCT03333941

Start Date

October 26 2017

End Date

May 8 2019

Last Update

July 30 2024

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Arizona Burn Center at Maricopa Integrated Health Systems

Phoenix, Arizona, United States, 85008

2

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States, 20010

3

Tampa General Hospital

Tampa, Florida, United States, 33606

4

University Medical Center

New Orleans, Louisiana, United States, 70112